CSPC Pharmaceutical Group Limited
1093
주식 순위
#1743
CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is... CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is dedicated to the development, production, and distribution of pharmaceutical goods. Its operations span the globe, with a significant presence in the People's Republic of China, across Asia, in the Americas, and throughout Europe. The company structures its business activities into three main divisions: Finished Drugs, Bulk Products, and Functional Food and Other ventures. The company's extensive portfolio of finished drugs encompasses treatments for a wide range of conditions. Key offerings include NBP (available as soft capsules and injections) for acute ischemic stroke, and Oulaining (capsules and injections) addressing mild to moderate memory and cognitive impairments. For neurological disorders, Enxi targets adult idiopathic Parkinson's disease. In oncology, Duomeisu treats lymphoma, multiple myeloma, ovarian and breast cancers, alongside other malignant tumors, while Jinyouli aids in preventing chemotherapy-induced leucopenia and infections, and Keaili is prescribed for breast cancer. Further therapeutic areas covered by CSPC include various infections, with products such as Shuluoke, Nuomoling, Weihong, and Xinweihong. Cardiovascular health is addressed by Xuanning for hypertension and Encun to avert atherosclerotic thrombosis events. Qixiao provides relief for upper respiratory tract infections, and diabetes management is supported by Linmeixin and Shuanglexin. Bone health solutions include Gubang and Gubangjia for postmenopausal osteoporosis. Additionally, Gaoshunsong offers relief for a broad spectrum of inflammatory and pain-related conditions, including arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursitis, tenosynovitis, acute gout, dysmenorrhea, toothache, postoperative pain, lower back pain, sprains, strains, and other soft tissue injuries. Other notable products include Debixin for various types of ulcers and Qimaite for acute and chronic pain management. Beyond finished pharmaceuticals, CSPC also supplies active pharmaceutical ingredients (APIs) like antibiotics, vitamin C, and caffeine. The company further diversifies into functional foods, glucose products, and provides healthcare services. Originally established in 1992, the company initially operated under the name China Pharmaceutical Group Limited before adopting its current designation, CSPC Pharmaceutical Group Limited, in March 2013. Its primary corporate office is situated in Shijiazhuang, within the People's Republic of China.
주가
$1.06
시가총액
$12.14B
변동 (1일)
-3.97%
변동 (1년)
-2.20%
국가
CN
거래 CSPC Pharmaceutical Group Limited (1093)
카테고리
Healthcare
CSPC Pharmaceutical Group Limited (1093)의 P/E 비율
October 2026 기준 P/E 비율 TTM: 10.93
CSPC Pharmaceutical Group Limited의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 10.93입니다. 2024년 말 기준 P/E 비율은 12.73였습니다.
CSPC Pharmaceutical Group Limited의 P/E 비율 기록 (2003 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 10.93 | -57.21% |
| 2025 | 25.55 | 100.66% |
| 2024 | 12.73 | -13.19% |
| 2023 | 14.67 | -6.65% |
| 2022 | 15.71 | -14.46% |
| 2021 | 18.37 | -5.49% |
| 2020 | 19.43 | -37.71% |
| 2019 | 31.20 | 41.73% |
| 2018 | 22.01 | -48.49% |
| 2017 | 42.73 | 63.02% |
| 2016 | 26.21 | -21.86% |
| 2015 | 33.55 | -16.97% |
| 2014 | 40.40 | -8.07% |
| 2013 | 43.95 | 2,247.39% |
| 2012 | 1.87 | -73.39% |
| 2011 | 7.04 | -32.64% |
| 2010 | 10.44 | 35.15% |
| 2009 | 7.73 | 58.22% |
| 2008 | 4.88 | -51.33% |
| 2007 | 10.04 | -92.16% |
| 2006 | 128.04 | 1,028.92% |
| 2005 | 11.34 | -6.45% |
| 2004 | 12.12 | 72.98% |
| 2003 | 7.01 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 40.53 | 270.68% |
US
|
|
| 38.50 | 252.09% |
US
|
|
| 80.21 | 633.65% |
US
|
|
| 116.96 | 969.71% |
US
|
|
| 22.25 | 103.49% |
CH
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.